Edward Chu Selected Research

PHY 906

1/2019	Cancer Biomarkers for Integrative Oncology.
1/2018	Wedding Rigorous Scientific Methodology and Ancient Herbal Wisdom to Benefit Cancer Patients: The Development of PHY906.
12/2014	The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).
6/2011	A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
9/2010	Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).
10/2009	Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edward Chu Research Topics

Disease

55	Neoplasms (Cancer) 03/2022 - 07/2003
40	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2000
17	Colonic Neoplasms (Colon Cancer) 12/2021 - 08/2003
4	Diarrhea 01/2018 - 04/2009
3	Chronic Disease (Chronic Diseases) 11/2021 - 01/2021
3	Thrombocytopenia (Thrombopenia) 12/2019 - 01/2017
3	Anemia 01/2017 - 05/2006
3	Vomiting 01/2017 - 04/2009
3	Fatigue 01/2017 - 05/2006
2	Neutropenia 12/2019 - 04/2009
2	Adenocarcinoma 01/2019 - 01/2018
2	Pancreatitis 01/2019 - 02/2014
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2019 - 04/2006
2	Microsatellite Instability 12/2018 - 11/2002
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018 - 10/2012
2	Vulvar Neoplasms (Vulvar Cancer) 11/2017 - 01/2017
2	Nausea 01/2017 - 04/2009
2	Leukopenia 01/2017 - 01/2017
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 02/2015
2	Hemorrhage 02/2014 - 03/2011
2	Leukemia 07/2013 - 11/2008
2	Fibrosis (Cirrhosis) 07/2012 - 01/2012
1	Cancer Pain 01/2022
1	Testicular Neoplasms (Testicular Cancer) 01/2022
1	Triple Negative Breast Neoplasms 01/2022
1	Atrial Fibrillation 11/2021
1	Lymphopenia (Lymphocytopenia) 10/2021
1	Chest Pain (Chest Pains) 01/2021
1	Tachycardia (Tachyarrhythmias) 11/2020
1	Febrile Neutropenia 12/2019
1	Hyponatremia 12/2019
1	Peripheral Nervous System Diseases (PNS Diseases) 12/2019
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2019

Drug/Important Bio-Agent (IBA)

15	Fluorouracil (Carac)FDA LinkGeneric 01/2019 - 07/2003
9	Capecitabine (Xeloda)FDA Link 12/2021 - 04/2005
7	Irinotecan (Camptosar)FDA LinkGeneric 01/2018 - 04/2005
6	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2021 - 04/2005
6	PHY 906IBA 01/2019 - 10/2009
5	Cytotoxins (Cytolysins)IBA 12/2019 - 04/2005
5	Pharmaceutical PreparationsIBA 01/2019 - 01/2006
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2006
4	veliparibIBA 01/2022 - 01/2017
4	Bevacizumab (Avastin)FDA Link 10/2021 - 05/2004
4	3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA 11/2020 - 01/2017
4	Biological ProductsIBA 01/2014 - 03/2004
4	Small Interfering RNA (siRNA)IBA 04/2013 - 02/2004
4	Thymidylate SynthaseIBA 01/2011 - 11/2001
4	Cetuximab (Erbitux)FDA Link 12/2010 - 02/2004
4	ErbB Receptors (EGF Receptor)IBA 10/2007 - 02/2003
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2017
3	ElectrolytesIBA 10/2021 - 01/2017
3	Cisplatin (Platino)FDA LinkGeneric 11/2017 - 01/2017
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017 - 04/2005
2	AntigensIBA 01/2022 - 10/2007
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2019 - 01/2017
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2019 - 01/2017
2	regorafenibIBA 01/2019 - 03/2015
2	Leucovorin (Folinic Acid)FDA Link 01/2018 - 10/2010
2	DNA (Deoxyribonucleic Acid)IBA 11/2017 - 05/2003
2	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 11/2017 - 01/2017
2	Phosphotransferases (Kinase)IBA 11/2017 - 01/2017
2	DeoxyribonucleotidesIBA 01/2017 - 08/2011
2	protein kinase DIBA 03/2015 - 05/2014
2	Proteins (Proteins, Gene)FDA Link 01/2014 - 07/2007
2	Antineoplastic Agents (Antineoplastics)IBA 07/2013 - 04/2005
2	Panitumumab (Vectibix)FDA Link 12/2010 - 05/2006
2	Growth Factor ReceptorsIBA 05/2010 - 10/2007
2	Monoclonal AntibodiesIBA 10/2007 - 04/2006
2	Alkylating AgentsIBA 01/2006 - 03/2005
1	PlatinumIBA 01/2022
1	Opioid Analgesics (Opioids)IBA 01/2022
1	Azacitidine (5 Azacytidine)FDA Link 01/2022
1	pembrolizumabIBA 01/2022
1	dimemorfan (AT 17)IBA 11/2021
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 11/2021
1	ARQ 197IBA 10/2021
1	Tenofovir (Viread)FDA Link 11/2020
1	Emtricitabine (Emtriva)FDA Link 11/2020
1	Troponin IIBA 11/2020
1	Carboplatin (JM8)FDA LinkGeneric 12/2019
1	honokiolIBA 01/2019
1	bruceantinolIBA 01/2019
1	2-bromolysergic acid diethylamide (BOL)IBA 01/2019
1	sulforaphaneIBA 01/2019
1	Focal Adhesion Kinase 2IBA 01/2019
1	Tumor Biomarkers (Tumor Markers)IBA 01/2019
1	Immune Checkpoint InhibitorsIBA 12/2018
1	XELOXIBA 01/2018
1	CytokinesIBA 01/2018

Therapy/Procedure

30	Therapeutics 01/2019 - 02/2004
27	Drug Therapy (Chemotherapy) 01/2022 - 01/2000
10	Palliative Care (Palliative Therapy) 03/2022 - 03/2014
5	Adjuvant Chemotherapy 01/2017 - 11/2002
2	Complementary Therapies (Alternative Medicine) 01/2019 - 11/2017
2	Combination Drug Therapy (Combination Chemotherapy) 01/2016 - 11/2008
2	Precision Medicine 02/2014 - 08/2013
1	Immunomodulation 01/2022
1	Catheters 11/2021
1	Electrodes (Electrode) 11/2021
1	Length of Stay 01/2021